Bronzwaer S, Lönnroth A, Haigh R
European Commission, DG Health and Consumer Protection, Luxembourg.
Euro Surveill. 2004 Jan;9(1):30-4. doi: 10.2807/esm.09.01.00441-en.
In 2001 the European Commission presented a 'Community strategy against Antimicrobial Resistance'. In previous years, the problem was addressed through an increasing number of isolated measures, but in this strategy the Commission outlined a comprehensive European Community approach across all sectors. The strategy consists of fifteen actions in four key areas: surveillance, prevention, research and product development, and international cooperation. An important part of this strategy is the 'Council Recommendation on the prudent use of antimicrobial agents in human medicine'. The Recommendation provides a detailed set of public health actions to contain antimicrobial resistance. This paper presents the eleven points of action of the strategy that are directly related to human medicine, and discusses related European Community activities. Under the new public health programme as well as under the research programme of the European Union, antimicrobial resistance is a key priority.
2001年,欧盟委员会提出了一项“欧洲共同体抗微生物药物耐药性防治战略”。在过去几年中,这一问题是通过越来越多的孤立措施来解决的,但在该战略中,委员会概述了一项涵盖所有部门的全面的欧洲共同体方法。该战略包括四个关键领域的十五项行动:监测、预防、研究与产品开发以及国际合作。该战略的一个重要部分是“关于在人类医学中谨慎使用抗微生物药物的理事会建议”。该建议提供了一套详细的公共卫生行动,以控制抗微生物药物耐药性。本文介绍了该战略中与人类医学直接相关的十一项行动要点,并讨论了欧洲共同体的相关活动。在新的公共卫生计划以及欧盟的研究计划下,抗微生物药物耐药性都是关键优先事项。